Founded in 1999,  Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox.  The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development.

    * High-throughput ADME screening
    * Customised ADME assays
    * In silico ADME predictive modeling
    * In vitro toxicology

Life Sciences

Cyprotex

Dr. Anthony Baxter

Phil Butler

Paul Walker

Stephen Madden

The Research and Development Scientists team at Cyprotex focuses on advancing drug discovery through high-throughput ADME (Absorption, Distribution, Metabolism, and Excretion) screening and customized assays. They utilize in vitro and in silico modeling to predict ADME properties and assess toxicology, ensuring the safety and efficacy of new compounds. This multidisciplinary team collaborates closely to develop innovative methodologies that enhance the understanding of pharmacokinetics and toxicology in drug development.

Research and Development Scientists

About

Team members

Other teams at Cyprotex

Leadership Team

Business Development Team